Company Performance - Alkermes reported quarterly earnings of $0.73 per share, missing the Zacks Consensus Estimate of $0.78 per share, but showing an increase from $0.64 per share a year ago, resulting in an earnings surprise of -6.41% [1] - The company posted revenues of $378.14 million for the quarter ended September 2024, which was 2.06% below the Zacks Consensus Estimate and a decrease from $380.94 million year-over-year [1] - Over the last four quarters, Alkermes has surpassed consensus EPS estimates only once and has topped consensus revenue estimates two times [1] Future Outlook - The immediate price movement of Alkermes' stock will largely depend on management's commentary during the earnings call and future earnings expectations [2] - The current consensus EPS estimate for the upcoming quarter is $0.78 on revenues of $377.63 million, while for the current fiscal year, the estimate is $2.69 on revenues of $1.51 billion [4] - The estimate revisions trend for Alkermes is currently unfavorable, resulting in a Zacks Rank 4 (Sell), indicating expected underperformance in the near future [4] Industry Context - The Medical - Biomedical and Genetics industry, to which Alkermes belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable industry outlook [5] - Alnylam Pharmaceuticals, another company in the same industry, is expected to report a quarterly loss of $0.51 per share, reflecting a year-over-year change of -144.4%, with revenues anticipated to be $529.8 million, down 29.4% from the previous year [5]

Exhibit 99.1 1 Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Katie Joyce +1 781 249 8927 Alkermes plc Reports Third Quarter 2024 Financial Results — Third Quarter Revenues of $378.1 Million — — Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year — — GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 — — Company Reiterates 2024 Financial Expectations — DUBLIN, Oct. 24, 2024 — ...

— Third Quarter Revenues of $378.1 Million —— Net Sales of Proprietary Products Increased Approximately 18% Year-Over-Year —— GAAP Net Income from Continuing Operations of $92.8 Million and Diluted GAAP Earnings per Share from Continuing Operations of $0.56 —— Company Reiterates 2024 Financial Expectations —DUBLIN, Oct. 24, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2024."Our third quarter financial results reflect strong year-over-year growth ...

In its upcoming report, Alkermes (ALKS) is predicted by Wall Street analysts to post quarterly earnings of $0.80 per share, reflecting an increase of 25% compared to the same period last year. Revenues are forecasted to be $388.81 million, representing a year-over-year increase of 2.1%.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 3.4% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during t ...

Group 1 - Alkermes plc will host a conference call and webcast presentation on October 24, 2024, at 8:00 a.m. ET to discuss its third quarter financial results [1] - The webcast and accompanying slides will be available on Alkermes' website, and a replay will be accessible approximately two hours after the event [1] - The company is a global biopharmaceutical firm focused on developing innovative medicines in neuroscience, with a portfolio addressing alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [2] Group 2 - Alkermes has a pipeline of clinical and preclinical candidates for neurological disorders, including narcolepsy and idiopathic hypersomnia [2] - The company is headquartered in Ireland, with additional offices in Massachusetts and a manufacturing facility in Ohio [2] - For investor relations inquiries, Jamie Constantine can be contacted at +1 781 873 2402 [2]

DUBLIN, Sept. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that it will host an investor event for financial analysts and institutional investors on Wednesday, Oct. 9, 2024 starting at 10:00 a.m. EDT in Waltham, Mass. Members of Alkermes' Research & Development team will review the company's orexin portfolio and development strategy. The event will also feature a clinician and thought leader panel discussion. A question and answer session will follow the presentations.The event will ...

̶  Data From Narcolepsy Type 2 Cohort of ALKS 2680 Phase 1b Study to be Presented in Oral Presentation  ̶̶  Data From Idiopathic Hypersomnia Cohort of ALKS 2680 Phase 1b Study Accepted for Poster Presentation  ̶DUBLIN, Sept. 23, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present clinical data from its phase 1b study of ALKS 2680 in patients with narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) at the European Sleep Research Society's (ESRS) 27th Congress, Sleep Europe 2 ...

Core Points - Alkermes plc announced the opening of applications for the 7th annual Alkermes Pathways Research Awards program, which will accept applications from September 20, 2024, to November 30, 2024 [1] - The program aims to support early-career researchers focused on advancing understanding of schizophrenia and bipolar disorder, offering grants of up to $100,000 per project [1][4] - Since its inception in 2018, the program has awarded approximately $2.5 million to 25 researchers, leading to multiple journal publications and presentations [5] Program Details - The Alkermes Pathways Research Awards program is designed for early-career investigators who are M.D.s, Ph.D.s, or equivalent, within five years of their initial academic appointment or current post-doctoral fellows affiliated with U.S. medical or research institutions [4] - An independent review committee of specialists in relevant fields will evaluate the applications [4] - The program has been recognized for its impact on supporting researchers, with some recipients obtaining additional funding from the NIH based on their Pathways-funded research [3] Company Overview - Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in neuroscience, with a portfolio addressing alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder [6] - The company is headquartered in Ireland, with additional offices and facilities in Massachusetts and Ohio [6]

DUBLIN, Aug. 28, 2024  /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat presentation at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, Sept. 4, 2024 at 2:35 p.m. EDT (7:35 p.m. BST). The live webcast may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.About Alkermes plcAlkermes plc is a global biopharmaceutical company that seeks to develop innovative medicines in the field of n ...

Alkermes plc (ALKS) announced the initiation of the phase II Vibrance-2 study, evaluating its novel, investigational, oral orexin 2 receptor agonist ALKS 2680 in adults with narcolepsy type 2 (NT2).The double-blind, placebo-controlled study will evaluate the safety and efficacy of ALKS 2680 as compared to placebo in adults with NT2. The primary endpoint of the Vibrance-2 study will check whether treatment with ALKS 2680 leads to a greater decrease in sleepiness versus placebo, as measured by the change in m ...